R
Richa Tyagi
Researcher at Johns Hopkins University School of Medicine
Publications - 34
Citations - 1468
Richa Tyagi is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Signal transduction & PI3K/AKT/mTOR pathway. The author has an hindex of 17, co-authored 30 publications receiving 1195 citations. Previous affiliations of Richa Tyagi include National Institutes of Health & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Human endogenous retrovirus-K contributes to motor neuron disease
Wenxue Li,Myoung Hwa Lee,Lisa J. Henderson,Richa Tyagi,Muzna Bachani,Joseph P. Steiner,Emilie Campanac,Dax A. Hoffman,Gloria von Geldern,Kory R. Johnson,Dragan Maric,H. Douglas Morris,Margaret R. Lentz,Katherine Pak,Andrew L. Mammen,Lyle W. Ostrow,Jeffrey D. Rothstein,Avindra Nath +17 more
TL;DR: It is shown that HERV-K is activated in a subpopulation of patients with sporadic amyotrophic lateral sclerosis (ALS) and that its envelope (env) protein may contribute to neurodegeneration and disease pathogenesis.
Journal ArticleDOI
Nodding syndrome may be an autoimmune reaction to the parasitic worm Onchocerca volvulus .
Tory P. Johnson,Richa Tyagi,Paul R. Lee,Myoung Hwa Lee,Kory R. Johnson,Jeffrey A. Kowalak,Abdel G. Elkahloun,Marie Medynets,Alina Hategan,Joseph Kubofcik,James J. Sejvar,Jeffrey Ratto,Sudhir Bunga,Issa Makumbi,Jane Ruth Aceng,Thomas B. Nutman,Scott F. Dowell,Avindra Nath +17 more
TL;DR: Initial evidence is provided supporting the hypothesis that nodding syndrome is an autoimmune epileptic disorder caused by molecular mimicry with O. volvulus antigens and suggests that patients may benefit from immunomodulatory therapies.
Journal ArticleDOI
Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia.
Srinivasa Subramaniam,Francesco Napolitano,Robert G. Mealer,Seyun Kim,Seyun Kim,Francesco Errico,Roxanne K. Barrow,Neelam Shahani,Richa Tyagi,Solomon H. Snyder,Alessandro Usiello +10 more
TL;DR: It is found that Ras homolog enriched in striatum (Rhes), a striatal-specific protein, binds to and activates mTOR, and Rhes−/− mice showed reduced striatal mTOR signaling and diminished dyskinesia, but maintained motor improvement on L-DOPA treatment, suggesting a therapeutic benefit for Rhes-binding drugs.
Journal ArticleDOI
Inositol Pyrophosphates Mediate the DNA-PK/ATM-p53 Cell Death Pathway by Regulating CK2 Phosphorylation of Tti1/Tel2
Feng Rao,Jiyoung Y. Cha,Jing Xu,Risheng Xu,M. Scott Vandiver,Richa Tyagi,Robert Tokhunts,Michael A. Koldobskiy,Chenglai Fu,Roxanne K. Barrow,Mingxuan Wu,Dorothea Fiedler,James C. Barrow,Solomon H. Snyder +13 more
TL;DR: It is demonstrated that IP7, formed by IP6K2, binds CK2 to enhance its phosphorylation of the TTT complex, thereby stabilizing DNA-PKcs and ATM and stimulating p53 phosphorylated at serine 15 to activate the cell death program in human cancer cells and in murine B cells.
Journal ArticleDOI
Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation.
TL;DR: A novel signaling pathway wherein NMDA receptor activation stimulates generation of nitric oxide, which S-nitrosylates glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which stabilizes Rheb that enhances mTOR signaling and drugs selectively targeting components of this pathway may offer novel approaches to the treatment of depression.